Tamoxifen Inhibits Cell Proliferation via Mitogen-Activated Protein Kinase Cascades in Human Ovarian Cancer Cell Lines in a Manner Not Dependent on the Expression of Estrogen Receptor or the Sensitivity to Cisplatin

Endocrinology

Volumn 145, Issue 3, 2004, Pages 1302-1313

  Mabuchi, Seiji ^a   Ohmichi, Masahide ^a   Kimura, Akiko ^a   Ikebuchi, Yoshihide ^a   Hisamoto, Koji ^a   Arimoto Ishida, Emi ^a   Nishio, Yukihiro ^a   Takahashi, Kazuhiro ^a   Tasaka, Keiichi ^a   Murata, Yuji ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CISPLATIN; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; RETINOBLASTOMA PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TAMOXIFEN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; OVARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION KINETICS;

ADENOCARCINOMA, PAPILLARY; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTIOXIDANTS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FLAVONOIDS; G1 PHASE; GENE EXPRESSION; HUMANS; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; OVARIAN NEOPLASMS; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 10744228193     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0709     Document Type: Article

References (46)

1. Love RR 1989 Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 7:803-815
2. Fuir BJA, Jordan VC 1984 The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205
3. Jordan VC, Murphy CS 1990 Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 11:578-610
4. Jaiyesimi IA, Buzdar AU, Deckaer DA, Hortobagyi GN 1995 Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13:513-529
5. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B 1996 Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol Oncol 62:4-6
6. Marth C, Sorheim N, Kaern J, Trope C 1997 Tamoxifen in the treatment of recurrent ovarian carcinoma. Int J Gynecol Cancer 7:256-261
7. Rao BR, Slotman BJ 1996 Endocrine role in ovarian cancer. Endocr Relat Cancer 3:309-326
8. Goldenberg GJ, Froses EK 1982 Drug and hormone sensitivity of estrogen receptor-positive and negative human breast cancer cells in vitro. Cancer Res 42:5147-5151
9. Taylor CM, Blanchard B, Zava DT 1984 Estrogen receptor-mediated and cytotoxic effects of antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res 44:1409-1414
10. Perry RR, Kang Y, Greaves BS 1995 Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 2:238-245
11. Gelmann EP 1996 Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog? J Natl Cancer Inst 88:224-226
12. Chen HM, Tritton TR, Kenny N, Absher M, Chiu JF 1996 Tamoxifen induces TGF β1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J Cell Biochem 61:9-17
13. Osbourne CK, Boldt DH, Clark GM, Trent JM 1983 Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 43:3583-3585
14. Perry RR, Kang Y, Greaves B 1995 Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 2:238-245
15. Otto AM, Paddenberg R, Schubert S, Mannherz HG 1996 Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J Cancer Res Clin Oncol 22:603-612
16. Cano E, Mahadevan LC 1995 Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 20:117-122
17. Duh J-L, Yu R, Jiao J-J, Matwyshyn GA, Li W, Tan T-H, Kong A-NT 1997 Activation of signal transduction kinases by tamoxifen. Pharmaceutical Res 14:186-189
18. Mandlekar S, Yu R, Tan T-H, Kong A-NT 2000 Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60:5995-6000
19. Zhang CC, Shapiro DJ 2000 Activation of the p38 mitogen-activated protein kinase pathway by estrogen or 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. J Biol Chem 275:479-486
20. KIP1 expression in estrogen receptor-negative lung cancer cells. Oncogene 18:4269-4274
21. Hurd C, Khattree N, Dinda S, Alban P, Moudgil VK 1997 Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells. Oncogene 15:991-995
22. Alblas J, Slager-Davidov R, Steenbergh PH, Sussenbach JS, van der Burg B 1998 The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells. Oncogene 16:131-139
23. Kimura A, Ohmichi M, Kurachi H, Ikegami H, Hayakawa J, Tasaka K, Kanada Y, Jikihara H, Matsuura N, Murata Y 1999 Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. Cancer Res 59:5133-5142
24. Sewing A, Wiseman B, Lloyd AC, Land H 1997 High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 17:5588-5597
25. Yen A, Roberson MS, Varvayanis S, Lee AT 1998 Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase(ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 58:3163-3172
26. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D, Murata Y 1999 Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 274:31648-31654
27. Jones J, Lagasse LD, Karlan BY 1994 Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines. Gynecol Oncol 55:421-426
28. Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, Fattorossi A, Isola G, Benedetti P, Mancuso S 1999 Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 79:257-263
29. Gundimeda U, Chen ZH, Gopalakrishna R 1996 Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 271:13504-13514
30. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF 1985 Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34:2583-2586
31. Green S, Walter P, Greene G, Krust A, Goffin C, Jensen E, Scrace G, Waterfield M, Chambon P 1986 Cloning of the human oestrogen receptor cDNA. J Steroid Biochem 24:77-83
32. Toyoshima F, Moriguchi T, Nishida E 1997 Fas induces cytoplasmic apoptotic responses and activation of the MKK7-JNK/SAPK and MKK6-p38 pathways independent of CPP32-like proteases. J Cell Biol 139:1005-1015
33. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T, Murata Y 2000 Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 60:5988-5994
34. Kimura A, Ohmichi M, Tasaka K, Kanda Y, Ikegami H, Hayakawa J, Hisamoto K, Morishige K, Hinuma S, Kurachi H, Murata Y 2000 Prolactin-releasing peptide activation of the prolactin promoter is differentially mediated by extracellular signal-regulated protein kinase and c-Jun N-terminal protein kinase. J Biol Chem 275:3667-3674
35. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K, Murata Y 2002 Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277:33490-33500
36. Ohmichi M, Matuoka K, Takenawa T, Saltiel AR 1994 Growth factors differentially stimulate the phosphorylation of Shc proteins and their association with Grb2 in PC-12 pheochromocytoma cells. J Biol Chem 269:1143-1148
37. Laemmli UK 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685
38. Ohmichi M, Koike K, Kimura A, Masuhara K, Ikegami H, Ikebuchi Y, Kanzaki T, Touhara K, Sakaue M, Kobayashi Y, Akabane M, Miyake A, Murata Y 1997 Role of mitogen-activated protein kinase pathway in prostaglandin F2α-induced rat puerperal uterine contraction. Endocrinology 138:3103-3111
39. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR 1995 A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92:7686-7689
40. Pang L, Sawada T, Decker SJ, Saltiel AR 1996 Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by NGF. J Biol Chem 270:13585-13588
41. Lazar DF, Wiese RJ, Brady MJ, Mastick CC, Waters SB, Yamauchi K, Pessin JE, Cuartrecasas P, Saltiel AR 1996 Mitogen-activated protein kinase kinase inhibitor does not block the stimulation of glucose utilization by insulin. J Biol Chem 270:20801-20807
42. Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S, Weinberg RA 1992 The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci 17:312-315
43. Weinberg RA 1995 The retinoblastoma protein and cell cycle control. Cell 81:323-330
44. Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B, Kidd VJ, Mak TW, Ingram AJ 2002 ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 277:12710-12717
45. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R 2001 Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20:147-155
46. McClay EF, Albright KD, Jones JA, Christen RD, Howell SB 1994 Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer 70:449-452